• 0 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Key Advances in Optimizing Outcomes in HR+/HER2- Early Breast Cancer: Straight From The European Oncology Congress
  Hematology-Oncology2023-11-30 19:00:00
  Did you know that adding a CDK 4/6 inhibitor to adjuvant endocrine therapy improves overall outcomes in HR-positive/HER2-negative early breast cancer?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Hypertension 281 global 1 1.0 9 1.0 1.0 Roundtable 0 1
  When, Where, and How to Incorporate Renal Denervation Into Your Hypertensive Practice
  Cardiology2023-11-29 19:00:00
  Renal denervation is approved. Which patients are likely to benefit?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Breast Cancer 840 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Shedding Light on the Role of Surgeon, Radiologist, and Oncologist
  Hematology-Oncology2023-11-20 19:00:00
  Do you consult with the multidisciplinary team (MDT) when making treatment decisions for patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC)?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Atrial Fibrillation 390 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1
  Addressing Suboptimal Anticoagulation in Atrial Fibrillation: Uncoupling the Potential of Factor XI/XIa Inhibition for Stroke Prevention
  Cardiology2023-11-16 19:00:00
  Why target factor XI/XIa? Experts discuss the rationale, mechanism, and the latest phase 2 data.
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Breast Cancer 840 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1
  Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
  Hematology-Oncology2023-11-16 19:00:00
  What strategies are you using to individualize treatment of HR+/HER2- early breast cancer?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Melanoma 65 global 1 1.0 9 1.0 1.0 Clinical Review 0 1
  LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team
  Hematology-Oncology2023-11-15 19:00:00
  Are you familiar with how to incorporate lymphocyte-activation gene 3 (LAG-3) inhibition into the management of metastatic melanoma? Find out more here!
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• 0 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Key Advances in Optimizing Outcomes in HR+/HER2- Early Breast Cancer: Straight From The European Oncology Congress
  Hematology-Oncology2023-11-30 19:00:00
  Did you know that adding a CDK 4/6 inhibitor to adjuvant endocrine therapy improves overall outcomes in HR-positive/HER2-negative early breast cancer?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Hypertension 281 global 1 1.0 9 1.0 1.0 Roundtable 0 1
  When, Where, and How to Incorporate Renal Denervation Into Your Hypertensive Practice
  Cardiology2023-11-29 19:00:00
  Renal denervation is approved. Which patients are likely to benefit?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Breast Cancer 840 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Shedding Light on the Role of Surgeon, Radiologist, and Oncologist
  Hematology-Oncology2023-11-20 19:00:00
  Do you consult with the multidisciplinary team (MDT) when making treatment decisions for patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC)?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Atrial Fibrillation 390 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1
  Addressing Suboptimal Anticoagulation in Atrial Fibrillation: Uncoupling the Potential of Factor XI/XIa Inhibition for Stroke Prevention
  Cardiology2023-11-16 19:00:00
  Why target factor XI/XIa? Experts discuss the rationale, mechanism, and the latest phase 2 data.
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Breast Cancer 840 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1
  Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
  Hematology-Oncology2023-11-16 19:00:00
  What strategies are you using to individualize treatment of HR+/HER2- early breast cancer?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Atrial Fibrillation 390 global 1 0.25 9 0.25 2 0.25 8 0.25 0.25 Clinical Brief 0 2
  What Should We Know About New-Onset Atrial Fibrillation During a Hospital Stay?
  Cardiology2023-11-17 00:00:00
  The current study assesses the risk for recurrent atrial fibrillation after transient atrial fibrillation and during hospitalization.
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Melanoma 65 global 1 1.0 9 1.0 1.0 Clinical Review 0 1
  LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team
  Hematology-Oncology2023-11-15 19:00:00
  Are you familiar with how to incorporate lymphocyte-activation gene 3 (LAG-3) inhibition into the management of metastatic melanoma? Find out more here!
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• 0 global 1 0.25 9 0.25 2 0.25 8 0.25 0.25 Clinical Brief 0 2
  What is the Impact of Primary Care on Surgical Outcomes?
  Family Medicine/Primary Care2023-11-15 00:00:00
  A new study examines how continuity of care with a single primary care provider can affect rates of emergency department use after surgery.
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Breast Cancer 840 global 1 0.25 9 0.25 0.25 Clinical Review 0 1
  Who Is Actually at High Risk? Determining the Risk of Recurrence for Patients With HR-Positive/HER2-Negative EBC
  Hematology-Oncology2023-11-15 00:00:00
  Do you know how to identify patients with HR-positive/HER2-negative early breast cancer who have a high risk for recurrence?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Gastroesophageal Reflux Disease 3032531 global 1 1.0 9 1.0 2 1.0 3 1.0 1.0 Roundtable 0 1
  A New Era in the Management of GERD
  Gastroenterology2023-11-06 19:00:00
  Are you up to date on the latest treatment for patients with gastroesophageal reflux disease (GERD)?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Skin Cancer 56 global 1 1.25 9 1.25 1.25 Roundtable 0 1
  Putting the Patient First: The Value of Personalized Medicine for Nonmelanoma Skin Cancers
  Hematology-Oncology2023-11-02 20:00:00
  How well do you personalize treatment for patients with nonmelanoma skin cancer?
  
  1.25ABIM MOC 1.25CME/CE 75MIN

  
  Save
• Gastroesophageal Reflux Disease 3032531 global 1 0.25 9 0.25 2 0.25 3 0.25 8 0.25 0.25 Clinical Brief 0 1
  Does Risk for Esophageal Cancer Differ for Erosive vs Nonerosive GERD?
  Gastroenterology2023-11-03 00:00:00
  A new study characterizes risk for esophageal adenocarcinoma based on findings from esophagogastroduodenoscopy.
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Cardiomyopathy 342 global 1 1.0 9 1.0 2 1.0 3 1.0 1.0 Roundtable 0 1
  Heart in Jeopardy: Innovations in Hypertrophic Cardiomyopathy
  Cardiology2023-10-30 20:00:00
  Play along in this engaging game show educational program on hypertrophic cardiomyopathy to test your knowledge and learn all about this topic!
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Influenza 1226 global 1 0.5 9 0.5 2 0.5 3 0.5 8 0.5 0.5 Clinical Brief 0 1
  Medscape Now! Hot Topics in Family Medicine October 2023 Part 2
  Family Medicine/Primary Care2023-10-26 00:00:00
  Learn about recent findings in arthritis prevalence, obesity drug-birth control pill interactions, and childhood flu vaccinations.
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Lung Cancer 5000186 global 1 1.25 9 1.25 1.25 Roundtable 0 1
  Precision Pathology as the Foundation for Precision Medicine: The Cornerstone of Care for NSCLC
  Pathology & Lab Medicine2023-10-23 20:00:00
  Do you know the best way to evaluate patients with non-small cell lung cancer (NSCLC) for driver mutations?
  
  1.25ABIM MOC 1.25CME/CE 75MIN

  
  Save
• Skin Cancer 56 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Simulation Situation: Individualizing Care for Patients With Skin Cancer
  Hematology-Oncology2023-10-22 20:00:00
  How would you treat these patients presenting with skin cancer?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Head and Neck Cancer 3004984 global 1 1.0 9 1.0 2 1.0 3 1.0 1.0 Roundtable 0 1
  Navigating the Patient Journey for LA SCCHN: A Look at Treatments for Today and Tomorrow
  Hematology-Oncology2023-10-18 20:00:00
  Do you know the best management for your patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Endometrial Cancer 3003432 global 1 0.25 9 0.25 0.25 Clinical Review 0 1
  Mismatch Repair-Deficient Solid Tumors: Underscoring Key Topics for Care
  Hematology-Oncology2023-10-13 00:00:00
  Did you know that immunotherapies demonstrate durable efficacy in patients with mismatch repair deficiency (dMMR) across tumor types?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save

Education For Your Patient

• Click here for access to online educational resources to share with your patients and their care partners

Policies and Requirements

• CME Policies
• State CME Requirements